Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

is what caught my immediate attention. There was a video a couple of years ago of this study early on which was a WOW moment showing outstanding but preliminary results

vimeo.com/110122034

This study was also presented at ASCO 2016 (Abstract No: 2552) where

ORR in the total, non-PTCL and PTCL populations was 52%; 33% (no CR) and 77% (38% CR) respectively

was pretty impressive when compared to

pralatrexate (P), romidepsin (R), and belinostat which have response rates ranging from 26%-29% as single agents.

Have to go but will look at the other abstracts in more detail later.